Ciclopirox nail lacquer
solution 8% has been shown to be effective in the treatment of dermatophyte
onychomycosis of mild to moderate severity Other studies report the effectiveness of
ciclopirox nail lacquer in
onychomycosis caused by Candida sp and nondermatophyte molds.
Ciclopirox nail lacquer may also be valuable in the treatment of early cases of
reinfection/relapse.
Ciclopirox nail lacquer
solution 8% may be an important adjunct to oral antifungal
therapy in certain presentations that might be poorly responsive to oral antifungal
therapy alone (eg, lateral
onychomycosis, longitudinal spike, dermatophytoma, and extensive
onycholysis). In some cases, surgical
therapies may need to be considered in addition to, or in preference to, topical nail lacquer treatment. The use of
ciclopirox nail lacquer
solution 8% as an adjunct to oral antifungal
therapy may widen the spectrum of activity of the combination because of the broad spectrum of coverage provided by the lacquer. The use of combination
therapy may be synergistic in terms of efficacy, enabling a reduction in the duration and cumulative dosage of oral
therapy. This could result in a decrease in the frequency and severity of systemic adverse effects associated with the oral antimycotics and the need to be vigilant about drug interactions. Studies need to be conducted to determine the place of combination oral and topical lacquer
therapy in the management of
onychomycosis.